2021-07-14| COVID-19

COVID-19: FDA Adds New Warning For a Rare Autoimmune Disorder to J&J’s Vaccine

by Daniel Ojeda
Share To

On July 12th, Johnson & Johnson announced that the FDA had added a new warning to its COVID-19 vaccine. This the second time the vaccine has been linked to a very rare but potentially deadly adverse event. The benefits of the vaccine outweigh the risks, but this development could contribute to vaccine hesitancy. 

The J&J vaccine was approved for emergency use in February 2021. The vaccine is 85% effective against the original COVID-19 variant, and it leads to the production of neutralizing antibodies against the Beta and Delta variants.

Additionally, J&J pledged to sell it on a not-for-profit basis. All these factors made the J&J vaccine an integral component of vaccination efforts around the world. The EU alone ordered 200 million doses, and last week it ordered an additional 40 million.


J&J’s Setbacks

The J&J vaccine suffered several setbacks, including manufacturing delays due to irregularities found at a Baltimore plant. The plant, owned by Emergent BioSolutions, was subcontracted to help with vaccine production. However, an inspection revealed a lack of sanitation and proper procedure. As a result, millions of doses were discarded.

Additionally, back in April, vaccination was paused due to a very rare but potentially life-threatening blood clotting. Although an extremely rare event, the CDC advised women younger than 50 years old to be aware. However, vaccination efforts resumed after it was determined that the benefits of the vaccine outweigh the risks. 


Guillain-Barré syndrome

After a review of the available data, the FDA added a warning for Guillain-Barre ́ syndrome (GBS), an autoimmune disease where the body’s immune system attacks the myelin fibers that coat neurons. This damage leads to weakness, tingling, problems walking, and difficulty with facial movement. In severe cases, it can lead to full-body paralysis.

The condition is extremely rare. Currently, more than 12 million people have received the J&J vaccine, and only 100 cases of GBS have been reported. That is 0.0008% of all people that received the vaccine. Of the cases, 95 required hospitalizations, and there was one reported death. Most of the cases were in men 50 older, and they occurred within 6 weeks post-inoculation. 

A higher rate of GBS has been observed with the AstraZeneca vaccine. This led European regulators to place a similar warning for that vaccine. Interestingly, the AstraZeneca and J&J vaccines use adenovirus-based vaccines. Crucially, the mRNA-based vaccines were not associated with a higher likelihood of developing GBS.

In a statement, J&J said, “We strongly support raising awareness of the signs and symptoms of rare events to ensure they can be quickly identified and effectively treated.”

Related Article: Moderna Looks Beyond COVID as it Doses First Patient With mRNA-Based Seasonal Flu Vaccine


© All rights reserved. Collaborate with us:
Related Post
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
New Orleans, USA
Hong Kong, China
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!